Search Clinical Trials in the European Union

Duration
Visits
Phase
Oral
Benefits
Drugs
Locations
Clinical Specialty
841-860 of 1,694 trials

Soft Tissue Sarcoma: MEK and PDL1 Inhibitor Combination

We are studying a new treatment combining two medications for patients with advanced soft tissue sarcoma. This trial aims to confirm safety and evaluate how well the treatment works in both children and adults.

Advanced or Metastatic CancerSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesOncologyPediatrics

Breast Cancer: Fezolinetant for Hot Flashes

We are studying whether fezolinetant can help reduce hot flashes in women with hormone receptor-positive breast cancer receiving hormone therapy. The trial also looks at how this treatment affects quality of life and sleep.

Hot Flashes1-2 yearsConfirmation phase (III)11-15 visitsStandard MedicinesPartially RemoteEndocrinologyOncology

Dementia with Lewy Bodies: Ambroxol Study

We are investigating whether Ambroxol can improve cognitive and functional abilities in people with early Dementia with Lewy Bodies. The study also looks at its effects on sleep disturbances and other related symptoms.

Dementia with Lewy Bodies1-2 yearsEfficacy phase (II)>20 visitsPost-Trial Drug AccessStandard MedicinesNeurologyPsychiatry

Knee Osteoarthritis: Diclofenac vs. Placebo

We are studying how diclofenac affects knee pain compared to a placebo in people with knee osteoarthritis. The trial also looks at how a special script may change patients' pain experiences.

Knee Osteoarthritis≤3 monthsMonitoring phase (IV)≤5 visitsStandard MedicinesCost ReimbursementInternal MedicineOrthopedics and Traumatology

Knee Surgery Pain Relief: Oral vs. IV Medications

We are comparing the effectiveness of oral pain relief to intravenous options for patients after knee arthroscopy. This study aims to see which method better manages pain and affects recovery.

Postoperative Pain Relief1-2 yearsMonitoring phase (IV)Standard MedicinesOrthopedics and TraumatologyOtolaryngology

Ulcerative Colitis: CICR-NAM Treatment Study

We are testing a new oral medication for people with mild to moderately active ulcerative colitis. The goal is to see if it helps improve symptoms and overall gut health.

Ulcerative Colitis1-2 yearsEfficacy phase (II)Confirmation phase (III)6-10 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementGastroenterology

Vitamin D3 Doses in Critically Ill Patients on Kidney Support

We are comparing two doses of vitamin D3 to see how they affect vitamin levels and health outcomes in ICU patients receiving kidney support. This study may help improve treatment for those with severe vitamin D deficiency.

Vitamin D DeficiencyMonitoring phase (IV)6-10 visitsNo PlaceboInvestigational MedicinesEndocrinologyNephrology

Brain Radionecrosis: Bevacizumab vs. Placebo

We are studying whether adding bevacizumab to standard corticosteroid therapy helps improve symptoms and reduce steroid use in patients with brain radionecrosis after radiotherapy. This trial also looks at safety and quality of life.

Brain Metastases and Radionecrosis>2 yearsConfirmation phase (III)≤5 visitsInvestigational MedicinesNeurologyOncology

Neuroendocrine Neoplasms: Metronomic Temozolomide Study

We are investigating the effects of low-dose Temozolomide in patients with advanced neuroendocrine neoplasms who are not fit for traditional treatments. The goal is to see if this approach can improve survival and quality of life.

Neuroendocrine Carcinoma>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesInternal MedicineOncology

Regorafenib for Recurrent Grade 2 and 3 Meningioma

We are studying whether Regorafenib can help patients with recurrent grade 2 and 3 meningiomas live longer without disease progression after surgery and radiotherapy. The trial also looks at overall survival, quality of life, and potential side effects.

Malignant Meningioma>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesNeurologyOncology

Cognitive Impairment in Parkinson's: Donepezil Study

We are studying whether donepezil can improve cognitive function in people with mild cognitive impairment due to Parkinson's disease. The trial will also evaluate its effects on mental health and quality of life.

Parkinson's Disease6-12 monthsEfficacy phase (II)6-10 visitsStandard MedicinesNeurology

Glioblastoma Treatment: Olaptesed Pegol with Radiation

We are studying the safety and effectiveness of olaptesed pegol combined with radiation therapy for patients with newly diagnosed glioblastoma and unmethylated MGMT promoter. This trial also explores how different doses may impact treatment outcomes.

Glioblastoma6-12 monthsSafety phase (I)Efficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesOncology

Diffuse Large B-Cell Lymphoma: Epcoritamab Plus Lenalidomide

We are studying whether a new combination of epcoritamab and lenalidomide can improve survival rates for adults with relapsed or refractory diffuse large B-cell lymphoma compared to standard treatments.

Relapsed or Refractory Diffuse Large B-Cell Lymphoma6-12 monthsConfirmation phase (III)11-15 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteHematologyOncology

Gastric Cancer: New Drug Combinations

We are studying new combinations of medications alongside chemotherapy for people with advanced gastric or gastroesophageal junction cancer. The goal is to see if these combinations improve treatment outcomes and safety.

Gastric AdenocarcinomaEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteOncology

Dexamethasone for Advanced Multiple Myeloma

We are studying a free treatment regimen of Dexamethasone for patients with advanced relapsed or refractory multiple myeloma. The goal is to see how well it works in improving response rates and quality of life.

Multiple Myeloma>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesHematologyOncology

Acute Myeloid Leukemia: Venetoclax and Azacitidine with Cusatuzumab

We are studying whether adding cusatuzumab to standard treatment helps newly diagnosed AML patients who can't have intensive therapy. This trial will also look at the safety and effectiveness of this combination.

Acute Myeloid LeukemiaEfficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesHematologyOncology

Systemic Sclerosis Prevention: Clopidogrel Study

We are investigating if Clopidogrel can reduce the risk of developing systemic sclerosis in patients with specific immune conditions and Raynaud phenomenon. The study compares its effects to a placebo over several years.

Raynaud Phenomenon>2 yearsEfficacy phase (II)Confirmation phase (III)Investigational MedicinesInternal MedicineRheumatology

The LIFE-MET Study: Metformin and Lifestyle Changes in Early Puberty

We are investigating how Metformin and lifestyle interventions may influence growth and development in girls with overweight and early puberty. The study looks at changes in body composition and pubertal progression.

Precocious Puberty and Overweight1-2 yearsEfficacy phase (II)≤5 visitsInvestigational MedicinesPartially RemoteEndocrinologyPediatrics

Chronic Kidney Disease: BI 690517 with Empagliflozin

We are studying whether a new daily pill can help prevent worsening kidney disease and heart problems in people with chronic kidney disease. Participants will compare this treatment to a placebo to see its effects.

Chronic Kidney Disease>2 yearsConfirmation phase (III)≤5 visitsInvestigational MedicinesCost ReimbursementPartially RemoteCardiologyNephrology

Treatment-Resistant PTSD: Mifepristone Study

We are investigating whether mifepristone can help reduce symptoms in people with treatment-resistant PTSD. This study compares its effects to a placebo to see if it offers better relief.

Post-traumatic Stress Disorder≤3 monthsEfficacy phase (II)Standard MedicinesPsychiatry